These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
502 related items for PubMed ID: 19287123
1. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene. Shahrokni A, Rajebi MR, Harold L, Saif MW. JOP; 2009 Mar 09; 10(2):215-20. PubMed ID: 19287123 [Abstract] [Full Text] [Related]
2. Capecitabine: a review. Walko CM, Lindley C. Clin Ther; 2005 Jan 09; 27(1):23-44. PubMed ID: 15763604 [Abstract] [Full Text] [Related]
3. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Shahrokni A, Rajebi MR, Saif MW. Clin Colorectal Cancer; 2009 Oct 09; 8(4):231-4. PubMed ID: 19822515 [Abstract] [Full Text] [Related]
7. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency]. Hooiveld EA, van Kuilenburg AB, Haanen JB, Westermann AM. Ned Tijdschr Geneeskd; 2004 Mar 27; 148(13):626-8. PubMed ID: 15083629 [Abstract] [Full Text] [Related]
9. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, Domingo E, Jones A, Howarth K, Freeman-Mills L, Johnstone E, Wang H, Love S, Scudder C, Julier P, Fernández-Rozadilla C, Ruiz-Ponte C, Carracedo A, Castellvi-Bel S, Castells A, Gonzalez-Neira A, Taylor J, Kerr R, Kerr D, Tomlinson I. Gut; 2015 Jan 27; 64(1):111-20. PubMed ID: 24647007 [Abstract] [Full Text] [Related]
10. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival. Saif MW, Hashmi S, Bell D, Diasio RB. Expert Opin Drug Saf; 2009 Sep 27; 8(5):507-14. PubMed ID: 19663627 [Abstract] [Full Text] [Related]
13. A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. Arbea L, Coma-Canella I, Martinez-Monge R, García-Foncillas J. World J Gastroenterol; 2007 Apr 14; 13(14):2135-7. PubMed ID: 17465463 [Abstract] [Full Text] [Related]
14. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil]. Ostapowicz A, Dołegowska B. Przegl Lek; 2012 Apr 14; 69(9):694-7. PubMed ID: 23401991 [Abstract] [Full Text] [Related]
15. Capecitabine induced cardiotoxicity: a case report and review of literature. Tunio MA, Hashmi A, Shoaib M. Pak J Pharm Sci; 2012 Jan 14; 25(1):277-81. PubMed ID: 22186341 [Abstract] [Full Text] [Related]
19. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Garcia AA, Blessing JA, Lenz HJ, Darcy KM, Mannel RS, Miller DS, Husseinzadeh N, Gynecologic Oncology Group. Gynecol Oncol; 2005 Mar 14; 96(3):810-7. PubMed ID: 15721430 [Abstract] [Full Text] [Related]